Canagliflozin and other SGLT2 inhibitors have been shown to reduce hospitalizations for HF and renal events2, 3, 4, 5 in patients with T2DM and recently also in patients without T2DM.5, 28. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.